Merck, a leading pharmaceutical, chemical and life science company, has obtained antitrust clearance from the United States Federal Trade Commission (FTC) for its planned acquisition of US-based life science company Sigma-Aldrich. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with its proposed acquisition of Sigma-Aldrich Corporation expired on December 22, 2014, thereby completing the US HSR Act antitrust notification and review requirement for the two companies. The combined company would be of great help to all life science customers and they would be able to provide a highly attractive set of products. In pharma and biopharma production, Sigma-Aldrich would complement Merck Millipore’s existing products and capabilities with additions along the entire value chain of drug production and validation.
This article is based on materials provided by:
Disclaimer: This article does not reflect any personal views of the authors/editors